Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.
Ying Huang
Advertisement
Articles by Ying Huang
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CGTlive®
1
Around the Helix: Cell and Gene Therapy Company Updates – December 17, 2025
2
The Implications of the Final Data From Hemgenix’s HOPE-B Trial
3
Guess the Therapy Answer December 17, 2025
4
What the Field of Cell and Gene Therapy Needs Most in the Current Moment
5